Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcino (Q36947423)
Jump to navigation
Jump to search
scientific article published on 13 July 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcino |
scientific article published on 13 July 2012 |
Statements
1 reference
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcino (English)
1 reference
Arlene A Forastiere
1 reference
Jill Gilbert
1 reference
Ju Whei Lee
1 reference
Athanassios Argiris
1 reference
Missak Haigentz
1 reference
Lawrence Eric Feldman
1 reference
Minyoung Jang
1 reference
Pattatheyil Arun
1 reference
Carter Van Waes
1 reference
13 July 2012
1 reference
1 reference
942-948
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference